Arcturus Therapeutics Ltd.
News
Here's Why We're Not Too Worried About Arcturus Therapeutics Holdings' (NASDAQ:ARCT) Cash Burn Situation
Simply Wall St Just because a business does not make any money, does not mean that the stock will go down. For example, although...\n more…
Does Arcturus Therapeutics Have the Potential to Rally 216.35% as Wall Street Analysts Expect?
Benzinga Arcturus Therapeutics (NASDAQ: ARCT) closed the last trading session at $21.10, gaining 2.7% over the past four weeks, but there could be plenty of upside left in the stock if short-term price targets set by Wall Street analysts are any guide.\n more…
Arcturus Therapeutics Receives Clearance of an Investigational New Drug Application to U.S. Food and Drug Administration for ARCT-032, an Investigational Inhaled mRNA Therapeutic to Treat Cys
Business Wire Arcturus Therapeutics Holdings Inc. (the Company, Arcturus, Nasdaq: ARCT), a global messenger RNA medicines company focused on the development of infectious disease vaccines and addressing unmet...\n more…
Does Arcturus Therapeutics (ARCT) Have the Potential to Rally 216.35% as Wall Street Analysts Expect?
Zacks Investment Research Arcturus Therapeutics (ARCT) closed the last trading session at $21.10, gaining 2.7% over the past four weeks, but there could be plenty of upside left in the stock if short-term price targets set by...\n more…
Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) Receives $71.40 Average Price Target from Brokerages
Zolmax Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT - Get Free Report) has been assigned a consensus recommendation of "Buy" from the eight ratings firms that are presently covering the company...\n more…
Arcturus Therapeutics to Attend Upcoming Investor & Scientific Conferences
Business Wire Arcturus Therapeutics Holdings Inc. (the Company, Arcturus, Nasdaq: ARCT), a global messenger RNA medicines company focused on the development of infectious disease vaccines and addressing unmet...\n more…